NANOBIOTIX Announces Expiration Of HSR Waiting Period Regarding The Agreement For Worldwide Co-Development And Commercialization Of Potential First-In-Class Radioenhancer NBTXR3
Portfolio Pulse from Happy Mohamed
Nanobiotix (NASDAQ:NBTX) announced the expiration of the HSR waiting period for its global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson. With this, the transaction has become effective and Nanobiotix is eligible to receive a $30 million upfront cash licensing fee.
August 15, 2023 | 8:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanobiotix's agreement with Janssen Pharmaceutica has become effective, making the company eligible to receive a $30 million upfront cash licensing fee.
The expiration of the HSR waiting period means that the agreement between Nanobiotix and Janssen Pharmaceutica is now effective. This is a positive development for Nanobiotix as it is now eligible to receive a $30 million upfront cash licensing fee, which could provide a significant boost to its cash flow and financial stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100